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Background: The identification of activating epidermal
growth factor receptor (EGFR) mutations is essential for
deciding therapy of non-small cell lung cancer (NSCLC)
patients. Circulating cell-free tumor DNA (cftDNA) holds
promise as a non-invasive methodology for tumor
monitoring in solid malignancies. Among advanced
NSCLC patients with an acquired resistance to EGFR-
tyrosine kinase inhibitors (TKIs), about 50% carry
T790M mutation, but its frequency in EGFR-TKI-naıve
patients and dynamic change during therapy remains
unclear. We hypothesized that EGFRmutation analysis
detection in cftDNA for NSCLC may be feasible for
monitoring treatment response to EGFR-TKIs and also
predict drug resistance.
Methods: EGFR sensitive mutations and T790M were
analyzed using digital PCR (d-PCR) (Quant studio 3D, life
technologies) in longitudinally (at baseline, at 4, 8, 20,
60, 120, 180, 270, 360 days) collected plasma samples
(n¼50) from 8 tissue-confirmed EGFR-mutant NSCLC
patients treated with an EGFR-TKI (Gefitinib N ¼ 4;
Erlotinib N ¼ 1; Afatinib N ¼ 3). DNA extracted from
plasma of 8 healty blood donors were used to detect the
specificity of EGFR mutant assay. Tumor assessment was
performed according to RECIST criteria 1.1 every two
months.
Results: The sensitivity of d-PCR in plasma versus tis-
sue was 71.4%. No EGFR mutation was present in the 8
control cases (specificity of 100%). Of four patients
who developed progression disease (PD), in the sam-
ples of progression, T790M was detected in 75% of
cases. The frequency of T790M in pre-TKI plasma
samples was of 37.5%. EGFR sensitive mutations
decreased at PD while T790M mutation increased in
75% of patients. Patients with concomitant pre-TKI
EGFR 19 deletion and T790M showed a PD before of 12
months compared to those with L858R. T790M was
frequently detected when new lesions were developed.
Four patients had T790M level decreased to undetect-
able level with longer PFS than those with detectable
T790M in blood.
Conclusion: Our results indicated that d-PCR was a
highly sensitive and useful method for detecting the
T790M mutation. Moreover, dynamically monitoring
T790M change might help determining EGFR-TKI resis-
tance. We thank Italian Association for Cancer Research
(AIRC) for supporting the study.
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Background: VeriStrat is a proteomic test validated to
be prognostic and predictive of overall survival (OS) to
EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR wild
type patients1. Serum Amyloid A1 (SAA1) and its two
truncated forms are responsible for 4 of the 8 peaks
overexpressed in Veristrat (VS) Poor classified patients.
The aim of the study was to explore if the microenvi-
ronment, with its complex network mediated by
inflammation and angiogenesis could represent the base
of the aggressive disease behavior of VS Poor subjects.
Moreover, the activity of the immune escape axis PD-1/
PD-L1 was explored.
Methods: Plasma biomarkers analyses were retrospec-
tively performed on plasma baseline samples of 244
patients enrolled in the PROSE trial1, while exploratory
tissue analysis was performed on 37 available histolog-
ical specimens. Circulating levels of HGF, VEGF, FGF,
Cromogranin A (CgA) and its pro- and anti-angiogenic
fragments (fragment 1-373 and 1-76, respectively)
were determined by an ELISA assay. PD-L1 expression
both on tumor cells and inflammatory elements of the
tumor microenvironment, and the tissue expression
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immunohistochemistry.
Results: CgA, HGF, VEGF, and FGF plasma levels were
statistically significantly higher in VS Poor subjects. High
plasma HGF levels were associated with lower PFS (3.4
versus 2.0 months, HR 1.67; 95% CI 1.25-2.23; p<0.001)
and OS (11.2 versus 6.4 months, HR 1.64; 95% CI 1.12-
2.23 p¼0.002). High PD-L1- tumor expression was
associated with worse PFS (5.9 versus 1.9 months, HR
2.28; 95% CI. 1.14-4.57; p<0.020) and a trend for lower
OS (14.6 versus 6.7 months, HR 1.47; 95% CI 0.85-2.53;
p¼0.165), but not significantly associated with VS status
(p¼0.656). At the multivariate analysis, CgA, HGF and
VEGF were independently associated with VS Poor sta-
tus. When clinical variables were also included (histol-
ogy and PS), multivariate analysis evidenced VEGF as the
only independent biomarker associated with the VS Poor
classification (p¼0.0013). Plasma HGF levels (HR 2.083;
95% CI. 1.306-3.321; p¼0.0021) and tumor PD-L1
expression (HR 2.579; 95% CI 1.036-6.421; p¼0.0417)
remained independent prognostic biomarkers for
shorter PFS.
Conclusion: Inflammation and angiogenesis appear to
be associated with the complex processes at the base
of the Veristrat signature. Plasma HGF levels and tu-
mor tissue PD-L1 are prognostic in terms of a worse
PFS, but VeriStrat remains the only highly reproduc-
ible clinically relevant biomarker associated with
OS. 1V Gregorc et al, The Lancet Oncology, p713,
15(7), 2014.
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Background: Third-generation tyrosine kinase in-
hibitors (3rd-TKIs) have proven effective in patients
with EGFR T790M who progress on prior EGFR TKI
therapy. Median progression-free survival (PFS) on a
3rd-TKI was 9-10 months for T790M+ patients
compared to 2-4 months for T790M- patients. PFS issimilar regardless of the specimen used to assess T790M
(tissue, plasma, or urine). Using simulation analytics, the
primary study aim was to assess the cost effectiveness of
a urine-testing strategy (UTS) versus a tissue-testing
strategy (TTS) for T790M detection in patients with
EGFR-positive lung adenocarcinoma and progression on
prior TKI therapy.
Methods: Analytics followed International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
and Society for Medical Decision Making (SMDM)
guidelines for Good Modeling Practices and Consoli-
dated Health Economic Evaluation Reporting Stan-
dards (CHEERS) for reporting findings. Outcomes and
economic implications were assessed from the
perspective of a third-party US payer, stratified by
government versus commercial fee rates. Endpoints
were PFS, overall survival (OS), direct medical re-
sources used (biopsies, chemotherapy, post-progres-
sion) and related costs. Data sources were published
reports of randomized drug trials and current data,
which includes accuracy results of tissue versus urine
testing (Trovagene, San Diego, CA), Medicare fee
schedules, and available adjustments for fees in com-
mercial markets. A state-transition analysis and Mar-
kov model tracked patients from stable disease,
progression, and to death. Full univariate and multi-
variate sensitivity analyses were performed to assess
the robustness of findings and factors that most
influenced outcomes and costs.
Results: Median PFS after treatment with 3rd-TKI was
3.4 months if tumor testing is T790M- versus 9.7
months if T790M+. Because urine testing can be used in
patients for whom biopsy cannot be performed or when
tissue testing reveals indeterminate results, PFS and OS
were slightly increased using the UTS. UTS resulted in
avoidance of a biopsy procedure, potential complica-
tions, and tissue-based molecular testing in approxi-
mately 48% of patients, leading to a 2- to 10-fold total
cost savings relative to the unit cost for a urine test.
Within the robust variations in input parameters, the
cost of a biopsy procedure/complications and tissue-
based molecular testing were the most influential
factors.
Conclusion: UTS is a dominant scenario to TTS by
saving costs and improving patient experience (e.g., PFS/
OS, and reduction in biopsy related complications). This
result is based on LEVEL I evidence from a large, ran-
domized trial that showed PFS is similar among patients
regardless of urine versus tissue testing for T790M
mutation status.
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